This post was originally published on this site A combination of tremelimumab plus Imfinzi (durvalumab) is no better than standard chemotherapy at extending the survival of people with metastatic non-small cell lung cancer (NSCLC) with a high tumor mutational burden, findings from a Phase 3 trial show. The open-label NEPTUNE trial (NCT02542293) was examining the…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
‘Disorder’ Film Festival Offers Look at Siblings Touched by Rare Diseases
This post was originally published on this site Rare diseases deeply affect not only the children who experience them, but also their healthy brothers and sisters, as their parents can attest. Two entries in November’s “Disorder: The Rare Disease Film Festival” will focus on what siblings go through, according to the San Francisco festival’s…
Research into Tumor Suppressor P53 in Ovarian Cancer Receives $1.8M NIH Grant
This post was originally published on this site A research team at the David Geffen School of Medicine at UCLA received a $1.8 million, five-year grant from the National Institutes of Health (NIH) to develop new therapeutic and preventive strategies for ovarian cancer based on the tumor suppressor p53. The team, led by Alice Soragni,…
European Commission Approves Empliciti Triple Combo for Advanced Multiple Myeloma
This post was originally published on this site The European Commission (EC) has approved Empliciti (elotuzumab) in combination with Pomalyst (pomalidomide) and low-dose dexamethasone for the treatment of adults with relapsed and refractory multiple myeloma. The therapy, collectively known as the EPd combo, is intended for patients who received at least two prior therapies, including…
Trial of Cutaneous T-cell Lymphoma Therapy WP1220 Fully Enrolled
This post was originally published on this site A Phase 2 clinical trial of WP1220, a potential topical treatment of cutaneous T-cell lymphoma (CTCL) lesions, has reached full patient enrollment. Developed by Moleculin Biotech, WP1220 is an inhibitor of phospho (p)-STAT3, the activated form of a transcription factor key for cancer cell growth and survival.…
Pexa-Vec Combo Unlikely to Benefit Advanced Liver Cancer Patients in Phase 3 Trial, Monitoring Group Says
This post was originally published on this site Adding the cancer vaccine Pexa-Vec to Nexavar (sorafenib), a standard of care, is not likely to improve overall survival of patients with advanced liver cancer, an interim analysis by the independent data monitoring committee of the PHOCUS Phase 3 trial reported. Based on these findings, the committee is…
Tecentriq-Abraxane Combo OK’d in EU to Treat Certain Advanced Triple-negative Breast Cancers
This post was originally published on this site The European Commission has approved the use of Roche‘s Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) chemotherapy to treat certain adults with advanced triple-negative breast cancer (TNBC), an aggressive and difficult-to-treat malignancy. The combo is intended for people whose tumors cannot be removed by surgery (unresectable), are locally advanced or…
FDA Clears Way for Trial of Immunotherapy in Advanced Prostate Cancer, Scripps Research Says
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has signed off on a clinical trial that will test CCW702, an immunotherapy developed by Calibr at Scripps Research, as a possible treatment of metastatic castration-resistant prostate cancer (mCRPC). CCW702 is a bispecific antibody, acting as a bridge between cancer and…
At NY Genome Center, Legal Expert Presents Ethical Dilemmas in Gene Editing
This post was originally published on this site Developing gene therapies for rare diseases is one thing. Creating gene-edited “designer babies” is quite another. German legal expert Timo Minssen outlined the potentially explosive ethical landmines surrounding such issues during a recent talk at the New York Genome Center. Minssen directs the Center for Advanced Studies…
Telix Enters Collaboration with DKFZ Researchers to Develop Image-Guided Surgery
This post was originally published on this site Telix Pharmaceuticals has established a collaboration agreement with a team of researchers from the German Cancer Research Center (Deutsches Krebsforschungszentrum, or DKFZ) to develop an innovative image-guided surgery for men with prostate cancer. Investigators from the DKFZ and Heidelberg University Clinic have been working on the development…
Expert Discusses Celsion’s Ovarian Cancer Immunotherapy GEN-1; Phase 1/2 Trial Still Enrolling
This post was originally published on this site The ovarian cancer immunotherapy candidate GEN-1, which is being tested in a Phase 1/2 clinical trial in newly diagnosed patients with advanced disease, was the focus of a recent call with a gynecologic oncology expert. The OVATION 2 trial (NCT03393884) is enrolling at 34 sites across the U.S. It…
GSK’s Belantamab Mafodotin Shows Promise for Relapsed or Refractory Multiple Myeloma
This post was originally published on this site GlaxoSmithKline’s investigational antibody-drug conjugate, belantamab mafodotin (GSK2857916), demonstrated a clinically meaningful overall response rate in hard-to-treat multiple myeloma patients in a Phase 2 trial, with the trial meeting its primary goal. Findings from the open-label DREAMM-2 study (NCT03525678) — which is assessing the treatment as a fourth-line…